News & Updates
Showing Pharmacy articles
Showing
5α-reductase inhibitors help reduce SARS-CoV-2 infection risk in men
Use of 5α-reductase inhibitors (5ARIs) appears to lower the risk of community-acquired infection with SARS-CoV-2 in men without prostate cancer, according to a study, noting that treatment with this drug class can help ease the burden of COVID-19.
Opioid use lowers LOS, deaths in nonmetastatic CRC patients
Use of opioids in the long term leads to shorter length of stay (LOS) and reduced inpatient mortality among patients hospitalized with nonmetastatic colorectal cancer (CRC), results of a study have shown. However, patients with cancer-related complications endure longer LOS and higher mortality than those admitted without such morbidities.
Does patient education improve influenza vaccination uptake?
Both individualized counselling (IC) and pamphlets have improved the uptake of influenza vaccination, but IC does not appear to be superior to pamphlets alone at improving vaccine acceptance, according to a Singapore study.
Belzutifan a ray of hope for VHL-associated renal cancer?
In a phase II study, the novel oral HIF*-2α inhibitor belzutifan showed promise for individuals with renal cell carcinoma (RCC) associated with von Hippel-Lindau (VHL) disease, a rare autosomal dominant hereditary disease associated with benign and malignant neoplasms, including clear-cell RCC, pancreatic neuroendocrine tumours, and CNS** and retinal hemangioblastomas.
First-line cabozantinib-atezolizumab boosts PFS in advanced HCC
The combination of cabozantinib and atezolizumab in the first-line setting significantly improved progression-free survival (PFS) compared with sorafenib in patients with advanced hepatocellular carcinoma (HCC), according to results of the phase III COSMIC-312 trial presented at ESMO Asia 2021.